Skip to main content
OpenTrials
Completed

NCT Number: NCT05840172

A Clinical Investigation to Assess the Effectiveness of Benzocaine in NRL Condoms in Healthy Adult Men Who Feel They Ejaculate Too Quickly During Vaginal Sex

The investigation is to evaluate the effectiveness of benzocaine in two NRL condoms compared with a standard NRL control without benzocaine in prolonging time to ejaculation in healthy adult men who feel they ejaculate too quickly during vaginal sex.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

SGS proderm GmbH

Hamburg, Germany

About this study

In this investigation, two NRL condoms with benzocaine paste (Test condom A and Test condom B) will be evaluated against a standard NRL male condom (Control condom) in prolonging time to ejaculation in healthy adult men who feel they ejaculate too quickly during vaginal sex.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Main Inclusion Criteria:

  • Subjects and their female partners have provided written informed consent.
  • Subjects and their female partners between the ages of >= 18 years and =< 60 years.
  • Subjects and their female partners must have no health condition in their medical history.
  • Subject must be sexually active having regular intercourse.
  • Subjects in a stable, monogamous, sexual relationship with the same female partner for more than or equal to 3 months.
  • Subject's female partner should already be on an established other highly effective form of non-barrier contraception, unless post-menopausal.
  • Subjects reporting a frequency of 'occasionally' to the Sexual Intercourse Self-Estimation Scale.

Main Exclusion Criteria:

  • Subject with a pregnant or breastfeeding female partner or the female partner desires to become pregnant during the clinical investigation.
  • Subject or his female partner with a current history of alcohol or drug abuse.
  • Subjects and their female partners with a history of or are suffering from anemia, coronary artery disease, impaired cardiac conduction, pulmonary disease, diabetes, and renal or hepatic disease.
  • Subjects and their female partners with a history of, suspected to have, or be at increased risk of methaemoglobinemia / complications related to ester anaesthetics which could trigger methemoglobinemia.
  • Subject and/or his female partner have a physical or psychological condition that would prevent them from following investigation procedures - including but not limited to the following:
  • urological disease,
  • ongoing significant psychiatric disorder not controlled by medication
  • history of surgery or injury to the pelvis, retroperitoneal surgery, radiotherapy, multiple sclerosis, spinal cord injury, chronic inflammation of the prostate or urethra
  • relevant previous or planned genital surgery
  • female partner that has been diagnosed with or treated for vaginal complaints (including vaginal dryness)
  • any broken skin or wounds in the genital area.
  • Subjects on medication that is contraindicated, which may affect erection.
  • Subject and/or his female partner have any medication which may affect the safety of the subject, including but not limited to benzocaine drug interactions such as cholinesterase inhibitors.
  • Subject and/or his female partner is using or intends to continue to use antibiotics of the sulphonamide type.
  • Subject with premature ejaculation, erectile dysfunction, hypo or hyperthyroidism, hypogonadism, hyperprolactinemia, ejaculatory dysfunction, haemorrhagic disorder, hepatitis B or C, human immunodeficiency virus (HIV) infection or having had penile implant surgery.
  • Subject that has been diagnosed or received treatment for PE (premature ejaculation).
  • Subjects with confirmed erectile dysfunction, hypo or hyperthyroidism, hypogonadism, hyperprolactinemia.
  • Confirmed diagnosis of male subjects with other forms of ejaculatory dysfunction.
  • Subjects that have had prior genital, prostatic or lower tract surgery.
  • Subjects with haemorrhagic disorder, hepatitis B or C, HIV infection or having had penile implant surgery, at any time in their past.
  • Either partner needed to use condoms for a specific STI protection.
  • Subjects and their female partners who have any relevant history of allergy including local anaesthetics, parabens, PABA, commercial hair dyes, paraphenylenediamine, lubricants and latex.

Treatment and study plan

Test condom A (NRL condom with 5% benzocaine paste)

Device

In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.

Test condom B (NRL condom with 3% benzocaine paste)

Device

In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.

Control NRL condom

Device

In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.

Primary outcomes

  1. To Determine the Effectiveness of Benzocaine of the Test Condom A Compared With the Control NRL Condom at Prolonging Time to Ejaculation

    Time frame: 4 weeks for each assessment period (intervention duration)

    Participants recorded the duration from vaginal entry to ejaculation for each condom use. The outcome was evaluated by the change from baseline with the Test Condom A compared to the Control NRL Condom, over a 4-week assessment period.

    This outcome was to measure the per participant's average IELT time per condom type. The Intravaginal Ejaculation Latency Time (IELT) is the duration from the start of vaginal entry (vaginal penetration into the female partner) until the start of intravaginal ejaculation (release of semen). It did not analyze all condom uses or sexual encounters as a unit, rather those were taken as an average per participant, in order to effectively run a Generalized Linear Mixed Model.

    This outcome measure data was collected and analyzed for 150 male participants.

Secondary outcomes

  1. To Determine the Effectiveness of Benzocaine of the Test Condom B Compared With the Control NRL Condom at Prolonging Time to Ejaculation

    Time frame: 4 weeks for each assessment period (intervention duration)

    Participants recorded the duration from vaginal entry to ejaculation for each condom use. The outcome was evaluated by the change from baseline with the Test Condom B compared to the Control NRL Condom, over a 4-week assessment period.

    This outcome was to measure the per participant's average IELT time per condom type. It did not analyze all condom uses or sexual encounters as a unit, rather those were taken as an average per participant, in order to effectively run a Generalized Linear Mixed Model.

    This outcome measure data was collected and analyzed for 150 male participants.

  2. To Determine the Effectiveness of Benzocaine of the Test Condom A and Test Condom B Compared With the Control NRL Condom at Prolonging Time to Ejaculation for an Increase of 2, 3 and 4 Minutes

    Time frame: 4 weeks for each assessment period (intervention duration)

    Participants recorded the duration from vaginal entry to ejaculation for each condom use. The outcome was evaluated by the proportion of participants who achieved an increase of 2, 3 and 4 minutes from baseline in each of the Test Condom A and Test Condom B compared to the Control NRL Condom.

    The odds ratio compares the odds of achieving a given duration increase (e.g., ≥2 minutes) with Test Condom A or B to the odds of achieving the same increase with the Control Condom. An odds ratio greater than 1 suggests the test condom is more effective than the control in helping participants reach that milestone.

    This outcome measure data was collected and analyzed for 150 male participants.

  3. To Evaluate the Sexual Pleasure When Using the Test Condom A or Test Condom B Compared With the Control NRL Condom

    Time frame: 4 weeks for each assessment period (intervention duration)

    The outcome was assessed by the measure of EMSEX (Event-level Male Sexual) pleasure scale questionnaire, a subject perceived questionnaire, at the end of a 4-week assessment period when using Test Condom A or Test Condom B compared with the Control NRL Condom. EMSEX pleasure scale is a 11-item scale which assesses sexual pleasure at the event level. For each item, the range spans the entirety of the potential range from 0 (zero) to 100 (one hundred).

    This outcome measure data was collected and analyzed for 150 male participants.

  4. To Evaluate the Subject's Improvement at "Lasting Longer" for Both the Test Condom A and Test Condom B Compared With the Control NRL Condom

    Time frame: 4 weeks for each assessment period (intervention duration)

    The outcome was assessed by the measure of Patient Global Impression of Change (PGIC), a subject perceived questionnaire, at the end of a 4-week assessment period when using Test Condom A or Test Condom B compared with the Control NRL Condom. The PGIC is a 7-point response scale (Very much better, Better, Little better, No change, Little worse, Worse, Very much worse).

    This outcome measure data was collected and analyzed for 150 male participants.

  5. Participant - Subject Perceived Questionnaire (SPQ)

    Time frame: 4 weeks for each assessment period (intervention duration)

    Upon completion of each condom assessment period, each participant was required to complete a SPQ. The questionnaire collected the following information (including but not limited to): experience with condom use, acceptability, preference and tolerability.

    This outcome measure data was collected and analyzed for 150 male participants.

  6. Total Clinical Failure Rate of Each Type of Condoms

    Time frame: 4 weeks for each assessment period (intervention duration)

    Number of clinical failure events per usages (clinical slippage or clinical breakage) reported by participants. The number of outcomes are based on the number of sexual encounters while wearing one of the three condoms being tested.

    This outcome measure data was collected and analyzed for 150 male participants.

  7. Overall Proportion of Participants With Adverse Events/Adverse Device Effects (AE/ADEs) - Male Participants

    Time frame: 19 weeks

    Overall proportion of participants with Adverse Events/Adverse Device Effects (AE/ADEs) i.e. the occurrence of one of more AE/ADE per participant.

    The result is presented by the counts of all AEs sorted by SOC and PT for male participants.

    This outcome measure data was collected and analyzed for 150 male participants.

  8. Overall Proportion of Participants With Adverse Events/Adverse Device Effects (AE/ADEs) - Female Participants

    Time frame: 19 weeks

    Overall proportion of participants with Adverse Events/Adverse Device Effects (AE/ADEs) i.e. the occurrence of one of more AE/ADE per participant.

    The result is presented by the counts of all AEs sorted by SOC and PT for male participants.

    This outcome measure data was collected and analyzed for 150 female participants.

Sponsors and collaborators

Lead sponsor

Reckitt Benckiser Healthcare (UK) Limited

Industry

Registry information

Official study title

An Open Label, Randomised, 3-way Cross-over, Single-centre, Clinical Investigation to Evaluate the Effectiveness of Benzocaine in Two NRL Condoms Compared With a Standard NRL Control Without Benzocaine in Prolonging Time to Ejaculation in Healthy Adult Men Who Feel They Ejaculate Too Quickly During Vaginal Sex

Acronym: NRL

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
May 3, 2023
Registry last updated
May 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.